SEARCH

SEARCH BY CITATION

References

  • 1
    Newman B, Austin MA, Lee M, King MC Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families Proc Natl Acad Sci USA 1988 85 304448 doi:10.1073/pnas.85.9.3044.
  • 2
    Claus EB, Risch N, Thompson WD Autosomal dominant inheritance of early onset breast cancer. Implications for risk prediction Cancer 1994 73 64351 doi:10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5.
  • 3
    Ford D, Easton DF, Stratton M, Narod S, Goldgar G, Devilee P et al Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families Am J Hum Genet 1998 62 67689 doi:10.1086/301749.
  • 4
    Roa BB, Boyd AA, Volcik K, Richards CS Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 Nat Genet 1996 14 1857 doi:10.1038/ng1096-185.
  • 5
    Evans DG, Eccles DM, Rahman N, Young K, Bulman M, Amir E et al A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO J Med Genet 2004 41 47480 doi:10.1136/jmg.2003.017996.
  • 6
    Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL et al Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies Am J Hum Genet 2003 72 111730 doi:10.1086/375033.
  • 7
    Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 2006 24 86371 doi:10.1200/JCO.2005.03.6772.
  • 8
    Hogg R, Freidlander M Biology of epithelial ovarian cancer: implications for screening women at high genetic risk J Clin Oncol 2004 22 131527 doi:10.1200/JCO.2004.07.179.
  • 9
    Rebbeck TR, Friebel T, Lynch HT, Neuhasen SL, van ‘t Veer L, Garber JE et al Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004 22 105562 doi:10.1200/JCO.2004.04.188.
  • 10
    Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber J et al Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations N Engl J Med 2002 346 161622 doi:10.1056/NEJMoa012158.
  • 11
    Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA et al Risk reducing saphingo-oophorectomy in women with a BRCA1 or BRCA2 mutation N Engl J Med 2002 346 160915 doi:10.1056/NEJMoa020119.
  • 12
    Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B et al Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006 296 185192 doi:10.1001/jama.296.2.185.
  • 13
    Vasen HF, Mecklin JP, Khan PM, Lynch HT The International Collaborative Group on Hereditary Non-polyposis Colorectal Cancer (ICG-HNPCC) Diseases of the Colon and Rectum 1991 34 42425 doi:10.1007/BF02053699.
  • 14
    Vasen HF, Watson P, Meckilin JP, Lynch HT New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC Gastroenterology 1999 116 145356 doi:10.1016/S0016-5085(99)70510-X.
  • 15
    Shia J, Klimstra DS, Nafa K, Offit K, Guillem JG, Markowitz AJ et al Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms Am J Surg Pathol 2005 29 96104 doi:10.1097/01.pas.0000146009.85309.3b.
  • 16
    Wu Y, Berends MJ, Mensink RG, Kempinga C, Sijmons RH, van der Zee AG et al Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations Am J Hum Genet 1999 65 129198 doi:10.1086/302612.
  • 17
    Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM et al A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines J Natl Cancer Inst 1997 89 175862 doi:10.1093/jnci/89.23.1758.
  • 18
    Syngal S, Fox EA, Eng C, Kolodner RD, Garber JE Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1 J Med Genet 2000 37 64145 doi:10.1136/jmg.37.9.641.
  • 19
    Wijnen J, Khan PM, Vasen H, van Der Klift H, Mulder A, van Leeuwen-Cornelisse I et al Hereditary nonpolyposis colorectal cancer families not complying with the Amsterdam criteria show extremely low frequency of mismatch-repair-gene mutations Am J Hum Genet 1997 61 32935.
  • 20
    Wijnen J, de Leeuw W, Vasen H, van der Klift H, Møller P, Stormorken A et al Familial endometrial cancer in female carriers of MSH6 germline mutations Nat Genet 1999 23 14244 doi:10.1038/13773.
  • 21
    Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G et al MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families J Clin Oncol 2001 19 407480.
  • 22
    Plaschke J, Engel C, Krüger S, Holinski-Feder E, Pagenstecher C, Mangold E et al Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. J Clin Oncol 2004 22 448694 doi:10.1200/JCO.2004.02.033.
  • 23
    Hendriks YM, Wagner A, Morreau H, Menko F, Stormorken A, Quehenberger F et al Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004 127 1725 doi:10.1053/j.gastro.2004.03.068.
  • 24
    Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomäki P et al Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer Gastroenterology 2000 118 82934 doi:10.1016/S0016-5085(00)70168-5.
  • 25
    Smith A, Moran A, Boyd MC, Bulman M, Shenton A, Smith L et al Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening J Med Genet 2007 44 1015 doi:10.1136/jmg.2006.043091.
  • 26
    Morrison PJ Insurance, unfair discrimination, and genetic testing Lancet 2005 366 87780 doi:10.1016/S0140-6736(05)67298-4.
  • 27
    Muir EG, Bell AJ, Barlow KA Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato-acanthomata of the face Br J Surg 1967 54 19195 doi:10.1002/bjs.1800540309.
  • 28
    Torre D Multiple sebaceous tumors Arch Dermatol 1968 98 54951 doi:10.1001/archderm.98.5.549.
  • 29
    Akhtar S, Oza KK, Khan SA, Wright J Muir–Torre syndrome: case report of a patient with concurrent jejunal and ureteral cancer and a review of the literature J Am Acad Dermatol 1999 41 68186 doi:10.1016/S0190-9622(99)70001-0.
  • 30
    Kruse R, Rütten A, Lamberti C, Hosseiny-Malayeri HR, Wang Y, Ruelfs C et al Muir–Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary non-polyposis colorectal cancer families defined by the Amsterdam criteria Am J Hum Genet 1998 63 6370 doi:10.1086/301926.
  • 31
    Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM et al The molecular basis of Turcot's syndrome N Engl J Med 1995 332 83947 doi:10.1056/NEJM199503303321302.
  • 32
    Lloyd KM 2nd, Dennis M Cowden's disease. A possible new symptom complex with multiple system involvement Ann Intern Med 1963 58 13642.
  • 33
    Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, Fix D et al Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients Cancer Res 2006 66 781017 doi:10.1158/0008-5472.CAN-06-1114.